Tags

Type your tag names separated by a space and hit enter

[Present role of continuous subcutaneous insulin infusion (CSII) by insulin pump in the treatment of diabetes mellitus].
Schweiz Med Wochenschr. 2000 Dec 02; 130(48):1854-61.SM

Abstract

Since the publication of the DCCT results, intensive insulin treatment, including continuous subcutaneous insulin infusion (CSII), has been considered one of the best methods for near-normal insulin delivery. The development of new, robust and easily programmable insulin pumps has led to readier acceptance of this therapy by physicians and patients. In clinical trials, CSII was found to be superior to multiple daily injection regimens in many cases. Patients with unsatisfactory glucose control, frequent hypoglycaemic events, and otherwise uncontrollable morning rises of blood glucose may in particular benefit from insulin pump therapy. Glucose control can even be improved in CSII if insulin lispro is used instead of regular human insulin, as demonstrated in many clinical investigations. Possible side effects of CSII are increased risk of ketoacidosis (e.g. in the case of catheter occlusion) and side effects at the infusion site. Since the successful development of devices for continuous glucose monitoring, the development of closed-loop systems has become more and more the focus of current clinical and technological research.

Authors+Show Affiliations

Pfützner A
Institut für Klinische Forschung und Entwicklung, Mainz (D). AndreasP@IKFE.de
Berger S
No affiliation info available
Spinas G
No affiliation info available

MeSH

Blood GlucoseClinical Trials as TopicDiabetes Mellitus, Type 1HumansInsulinInsulin Infusion Systems

Pub Type(s)

English Abstract
Journal Article
Review

Language

ger

PubMed ID

11132530

Citation

Pfützner, A, et al. "[Present Role of Continuous Subcutaneous Insulin Infusion (CSII) By Insulin Pump in the Treatment of Diabetes Mellitus]." Schweizerische Medizinische Wochenschrift, vol. 130, no. 48, 2000, pp. 1854-61.
Pfützner A, Berger S, Spinas G. [Present role of continuous subcutaneous insulin infusion (CSII) by insulin pump in the treatment of diabetes mellitus]. Schweiz Med Wochenschr. 2000;130(48):1854-61.
Pfützner, A., Berger, S., & Spinas, G. (2000). [Present role of continuous subcutaneous insulin infusion (CSII) by insulin pump in the treatment of diabetes mellitus]. Schweizerische Medizinische Wochenschrift, 130(48), 1854-61.
Pfützner A, Berger S, Spinas G. [Present Role of Continuous Subcutaneous Insulin Infusion (CSII) By Insulin Pump in the Treatment of Diabetes Mellitus]. Schweiz Med Wochenschr. 2000 Dec 2;130(48):1854-61. PubMed PMID: 11132530.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Present role of continuous subcutaneous insulin infusion (CSII) by insulin pump in the treatment of diabetes mellitus]. AU - Pfützner,A, AU - Berger,S, AU - Spinas,G, PY - 2001/1/2/pubmed PY - 2001/2/28/medline PY - 2001/1/2/entrez SP - 1854 EP - 61 JF - Schweizerische medizinische Wochenschrift JO - Schweiz Med Wochenschr VL - 130 IS - 48 N2 - Since the publication of the DCCT results, intensive insulin treatment, including continuous subcutaneous insulin infusion (CSII), has been considered one of the best methods for near-normal insulin delivery. The development of new, robust and easily programmable insulin pumps has led to readier acceptance of this therapy by physicians and patients. In clinical trials, CSII was found to be superior to multiple daily injection regimens in many cases. Patients with unsatisfactory glucose control, frequent hypoglycaemic events, and otherwise uncontrollable morning rises of blood glucose may in particular benefit from insulin pump therapy. Glucose control can even be improved in CSII if insulin lispro is used instead of regular human insulin, as demonstrated in many clinical investigations. Possible side effects of CSII are increased risk of ketoacidosis (e.g. in the case of catheter occlusion) and side effects at the infusion site. Since the successful development of devices for continuous glucose monitoring, the development of closed-loop systems has become more and more the focus of current clinical and technological research. SN - 0036-7672 UR - https://www.unboundmedicine.com/medline/citation/11132530/[Present_role_of_continuous_subcutaneous_insulin_infusion__CSII__by_insulin_pump_in_the_treatment_of_diabetes_mellitus]_ DB - PRIME DP - Unbound Medicine ER -